Keyword

DLL3

Description: DLL3 is a protein-coding gene that encodes a Notch ligand involved in developmental signaling and targeted cancer therapies.

Primary topic: Lung Cancer Research Studies (29%)

Wikidata ID: wiki/Q18035604

OpenAlex ID: keywords/dll3

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

2006 · Heidi S. Phillips, Samir Kharbanda, et al. · Cancer Cell · 3,144

PDF

Mash1regulates neurogenesis in the ventral telencephalon

1999 · Simona Casarosa, Carol Fode, et al. · Development · 639

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

2015 · Laura R. Saunders, Alexander J. Bankovich, et al. · Science Translational Medicine · 600

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

2023 · Myung-Ju Ahn, Byoung Chul Cho, et al. · New England Journal of Medicine · 592

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

2016 · Charles M Rudin, M Catherine Pietanza, et al. · The Lancet Oncology · 575

SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization

2020 · Marina K Baine, Min-Shu Hsieh, et al. · Journal of Thoracic Oncology · 524

PDF

ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs

2016 · Mark D. Borromeo, Trisha K. Savage, et al. · Cell Reports · 505

PDF

Unravelling the biology of SCLC: implications for therapy

2017 · Joshua K. Sabari, Benjamin H. Lok, et al. · Nature Reviews Clinical Oncology · 491

Mutations in the human Delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis

2000 · Michael P. Bulman, Kenro Kusumi, et al. · Nature Genetics · 393

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors

2018 · Julie George, Vonn Walter, et al. · Nature Communications · 377

PDF

Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo

1997 · Sally L. Dunwoodie, Domingos Henrique, et al. · Development · 368

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

2023 · Luis Paz-Ares, Stephane Champiat, et al. · Journal of Clinical Oncology · 339

PDF

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

2019 · Daniel Morgensztern, Benjamin Besse, et al. · Clinical Cancer Research · 326

PDF

Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism

2006 · Ayyakannu Ayyanan, Gianluca Civenni, et al. · Proceedings of the National Academy of Sciences · 294

The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands

2005 · Ena Ladi, James T. Nichols, et al. · The Journal of Cell Biology · 282

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

2021 · Fiona Blackhall, Kevin Jao, et al. · Journal of Thoracic Oncology · 280

The mouse pudgy mutation disrupts Delta homologue Dll3 and initiation of early somite boundaries

1998 · Kenro Kusumi, Eileen Sun, et al. · Nature Genetics · 275

AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

2020 · Michael J. Giffin, Keegan Cooke, et al. · Clinical Cancer Research · 259

PDF

Mind bomb 1 is essential for generating functional Notch ligands to activate Notch

2005 · Bon-Kyoung Koo, Hyoung-Soo Lim, et al. · Development · 247

Mutation of the LUNATIC FRINGE Gene in Humans Causes Spondylocostal Dysostosis with a Severe Vertebral Phenotype

2005 · D.B. Sparrow, G. Chapman, et al. · The American Journal of Human Genetics · 243

PDF

DLL3: an emerging target in small cell lung cancer

2019 · Dwight H. Owen, Michael J. Giffin, et al. · Journal of Hematology & Oncology · 239

PDF

Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids

2019 · N. Alcala, N. Leblay, et al. · Nature Communications · 223

PDF

Axial skeletal defects caused by mutation in the spondylocostal dysplasia/pudgy geneDll3are associated with disruption of the segmentation clock within the presomitic mesoderm

2002 · Sally L. Dunwoodie, Melanie Clements, et al. · Development · 220

Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer

2019 · Loredana Puca, Katie Gavyert, et al. · Science Translational Medicine · 213

Recapitulating the human segmentation clock with pluripotent stem cells

2020 · Mitsuhiro Matsuda, Yoshihiro Yamanaka, et al. · Nature · 206

PDF

Works count: 1,600

Citation count: 24,450